APA (7th ed.) Citation

A, O., V, G., J, G., A, K., A, B., B, M., . . . L, M. (2025). Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 35(4), 101644. https://doi.org/10.1016/j.ijgc.2025.101644

Chicago Style (17th ed.) Citation

A, Obermair, et al. "Phase 2b, Open-label, Single-arm, Multicenter Pilot Study of the Efficacy, Safety, and Tolerability of Dostarlimab in Women with Early-stage Mismatch Repair-deficient Endometrioid Endometrial Adenocarcinoma." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 35, no. 4 (2025): 101644. https://doi.org/10.1016/j.ijgc.2025.101644.

MLA (9th ed.) Citation

A, Obermair, et al. "Phase 2b, Open-label, Single-arm, Multicenter Pilot Study of the Efficacy, Safety, and Tolerability of Dostarlimab in Women with Early-stage Mismatch Repair-deficient Endometrioid Endometrial Adenocarcinoma." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 35, no. 4, 2025, p. 101644, https://doi.org/10.1016/j.ijgc.2025.101644.